论文部分内容阅读
目的观察FOLFIRI方案[伊立替康(CPT-11)+5-氟尿嘧啶(5-FU)+四氢叶酸钙(LV)]一线治疗晚期结直肠癌的临床疗效和不良反应。方法对43例晚期结直肠癌患者,采用FOLFIRI方案治疗。CPT-11180mg/m2,持续静脉滴入90min,第1天;四氢叶酸钙400mg/m2,静脉滴注(2h),第1天;氟尿嘧啶0.4g/m2,静脉推注(四氢叶酸钙之后用);氟尿嘧啶2.4g/m2,持续静脉灌注(经化疗泵灌注)46h。每14d重复。观察近期疗效及不良反应。结果 43例患者中,完全缓解(CR)1例(2.3%),部分缓解(PR)18例(41.9%),稳定(SD)12例(27.9%),疾病进展(PD)12例(27.9%)。不良反应主要为延迟性腹泻、中性粒细胞减少及胆碱能综合征。结论 FOLFIRI方案用于晚期结肠直肠癌一线治疗疗效肯定,耐受性好。
Objective To observe the clinical efficacy and side effects of FOLFIRI regimen [irinotecan (CPT-11) + 5-fluorouracil (5-FU) + leucovorin (LV) Methods Forty-three patients with advanced colorectal cancer were treated with FOLFIRI regimen. CPT-11180mg / m2, continuous intravenous infusion of 90min, on the first day; leucovorin 400mg / m2, intravenous drip (2h), on the first day; fluorouracil 0.4g / m2, intravenous injection ); Fluorouracil 2.4g / m2, continuous intravenous infusion (chemotherapy pump perfusion) 46h. Repeated every 14d. Observation of short-term efficacy and adverse reactions. Results Among the 43 patients, complete remission (CR) occurred in 1 patient (2.3%), partial response (PR) in 18 patients (41.9%), stable (SD) in 12 patients (27.9%) and disease progression %). Adverse reactions are mainly delayed diarrhea, neutropenia and cholinergic syndrome. Conclusion FOLFIRI regimen is effective and effective in first-line treatment of advanced colorectal cancer.